Retatrutide: The Triple-Agonist Peptide Overview
Retatrutide (development code: LY3437943) represents a paradigm shift in incretin-based peptide research. As the first triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, it has generated significant interest in the research community since its initial characterization. This article examines its molecular design, receptor pharmacology, published research data, and how it compares to established single and dual agonists.
Molecular Profile
| Development Code | LY3437943 |
| Class | Triple incretin receptor agonist (GIP/GLP-1/GCG-R) |
| Developer | Eli Lilly and Company |
| Amino Acids | 39 |
| Molecular Weight | ~4,750 Da |
| Half-Life | ~6 days (enabling weekly research dosing) |
| Backbone | Based on GIP sequence with engineered cross-reactivity |
| Fatty Acid | C-20 fatty diacid for albumin binding |
The Triple-Agonist Mechanism
Retatrutide is engineered to activate three distinct but interrelated receptor systems. Understanding each receptor's contribution is key to appreciating the compound's research value:
GIP Receptor (GIPR) - Primary Agonism
Glucose-dependent insulinotropic polypeptide receptor activation represents the peptide's primary agonist activity. GIP is an incretin hormone released from intestinal K-cells in response to nutrient intake. In research models, GIPR activation has been associated with enhanced insulin secretion, adipocyte lipid metabolism, and CNS-mediated effects on energy balance. Retatrutide demonstrates high GIPR binding affinity derived from its GIP-based backbone sequence.
GLP-1 Receptor (GLP-1R) - Secondary Agonism
GLP-1 receptor engagement provides the well-characterized incretin effects studied extensively with compounds like semaglutide and liraglutide. In research models, GLP-1R activation promotes insulin secretion, reduces glucagon release, and modulates gastric motility. Retatrutide's GLP-1R activity is engineered through strategic amino acid substitutions in the GIP backbone.
Glucagon Receptor (GCGR) - Tertiary Agonism
The glucagon receptor component is what distinguishes retatrutide from dual agonists like tirzepatide. GCGR activation in research models has been associated with increased hepatic lipid oxidation, elevated energy expenditure through thermogenesis, and mobilization of amino acid catabolism. The inclusion of glucagon agonism is a novel approach based on the hypothesis that controlled glucagon signaling may complement incretin effects.
Evolution of Incretin Agonists
Retatrutide represents the latest step in an evolutionary trajectory of incretin-based research peptides:
| Generation | Example | Receptor Targets | Available At |
|---|---|---|---|
| 1st Gen: Single Agonist | Semaglutide | GLP-1R only | From $49.99 |
| 2nd Gen: Dual Agonist | Tirzepatide | GIP-R + GLP-1R | From $79.99 |
| 3rd Gen: Triple Agonist | Retatrutide | GIP-R + GLP-1R + GCG-R | From $59.99 |
Published Research Data
Phase 1 Studies
Initial human pharmacology data for LY3437943 was published in The Lancet (Rosenstock et al., 2023), establishing the compound's pharmacokinetic profile and receptor engagement characteristics. Key observations from this research:
- Dose-dependent receptor engagement across all three target pathways
- Terminal half-life supporting once-weekly research dosing protocols
- Pharmacokinetic profile consistent with the C-20 fatty diacid albumin-binding design
Phase 2 Studies
A pivotal 48-week Phase 2 trial was published in the New England Journal of Medicine (Jastreboff et al., 2023), providing the most comprehensive research data to date:
- Evaluated multiple dosing levels (1mg through 12mg) across approximately 340 research participants
- Demonstrated dose-dependent biological effects across multiple metabolic endpoints
- The highest dose group showed the most pronounced metabolic effects observed with any single agent in the incretin agonist class
- Gastrointestinal tolerability profile was consistent with the GLP-1 receptor agonist class
Ongoing Research (Phase 3)
Multiple large-scale Phase 3 trials are currently underway under Eli Lilly's clinical development program, evaluating retatrutide across several research domains including metabolic endpoints, cardiovascular outcomes, and hepatic applications. These studies are expected to report results through 2026-2027.
Retatrutide vs Tirzepatide vs Semaglutide
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Targets | GLP-1R | GIPR + GLP-1R | GIPR + GLP-1R + GCGR |
| Half-Life | ~7 days | ~5 days | ~6 days |
| Amino Acids | 31 | 39 | 39 |
| Phase | Approved (Ozempic/Wegovy) | Approved (Mounjaro/Zepbound) | Phase 3 clinical trials |
| Glucagon Activity | None | None | Yes (thermogenesis) |
| Available Sizes | 5mg, 10mg, 20mg | 10-60mg | 5-60mg |
For researchers seeking to compare single, dual, and triple agonist approaches, running parallel studies with all three compounds provides the most comprehensive data on incretin pathway pharmacology. Our Semaglutide vs Tirzepatide comparison article provides additional detail on the first two generations.
Laboratory Handling
Reconstitution
Retatrutide is supplied as a lyophilized powder. Reconstitute with bacteriostatic water following standard protocols. The reconstituted solution should be clear and colorless.
Storage
- Lyophilized: -20°C for long-term storage; 2-8°C for up to 90 days
- Reconstituted: 2-8°C, use within 30 days, protect from light
- See our complete Peptide Storage & Stability Guide for detailed best practices
Available Research Quantities
| Size | Price | Recommended For |
|---|---|---|
| 5mg | $59.99 | Pilot studies, receptor binding assays |
| 10mg | $89.99 | Standard research protocols |
| 20mg | $149.99 | Extended studies, dose-response curves |
| 30mg | $169.99 | Multi-arm comparison studies |
| 50mg | $329.99 | Large-scale in-vitro research |
| 60mg | $369.99 | Institutional research programs |
Order Research-Grade Retatrutide
Triple-agonist peptide. 99.8% HPLC-verified purity. USA manufactured. 6 sizes available.
Shop Retatrutide